Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Yes. It is important to get any lump in your breast checked by a doctor, even if it is not painful. Not all lumps are cancerous, but some could be cysts or benign growth but only a medical professional can determine what it is.
When you think about breast cancer, what do you think of? A young woman with nipple discharge? Probably not. And that's because we often associate a lump as a sign of breast cancer, as well as assuming it only affects older women. But what about the other symptoms? There are some lesser known ind....
If you need a good cancer doctor in Kolkata, some experienced specialists are Dr. Chandrakanth MV, Dr. Rajib De, Dr. Tapti Sen, and Dr. Rajeev Sharan. They treat different types of cancer with the best care, including chemotherapy, radiation, and surgery. To find more doctors, check their availab....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
লেখা:Dr. Nitika Sharma - BDS
পর্যালোচনা করা হয়েছে:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.